Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS)
CNY 11.25
(2.18%)
CNY 11.25
(2.18%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 496.11 Million | 547.48 Million | 487.15 Million | 320.1 Million | 179.11 Million | 76.33 Million |
| Cost of Revenue | 31.99 Million | 39.06 Million | 29.58 Million | 15.55 Million | 15.22 Million | 11.66 Million |
| Gross Profit | 464.12 Million | 508.41 Million | 457.56 Million | 304.55 Million | 163.88 Million | 64.67 Million |
| Operating Expenses | 461.02 Million | 447.94 Million | 348.06 Million | 259.05 Million | 187.63 Million | 77.34 Million |
| Selling, General and Administrative Expenses | 284.64 Million | 318.59 Million | 262.67 Million | 193.61 Million | 118.74 Million | 37.6 Million |
| Research and Development Expenses | 114.72 Million | 121.98 Million | 56.35 Million | 42.72 Million | 52.11 Million | 30.62 Million |
| Other Expenses | 74.8 Million | 7.35 Million | 29.03 Million | 22.7 Million | 16.77 Million | 2.23 Million |
| Cost and Expenses | 493.02 Million | 487 Million | 377.65 Million | 274.6 Million | 202.86 Million | 89 Million |
| Operating Income | 3.4 Million | 69.14 Million | 101.58 Million | 48.68 Million | -23.75 Million | -21.22 Million |
| Interest Expense | 7.17 Million | 4.24 Million | 1.22 Million | 569.71 Thousand | 494.02 Thousand | 400.26 Thousand |
| Income Tax Expense | 4.17 Million | 17.07 Million | -773.64 Thousand | 12.55 Million | 33.1 Thousand | 19.49 Thousand |
| Earnings before Tax | 15.92 Million | 43.64 Million | 107.18 Million | 36.13 Million | -31 Million | -18.98 Million |
| Net Income | 17.55 Million | 26.57 Million | 107.96 Million | 23.57 Million | -31.04 Million | -19 Million |
| Earnings Per Share Basic | 0.04 | 0.07 | 0.27 | 0.06 | -0.08 | -0.09 |
| Earnings Per Share Diluted | 0.04 | 0.07 | 0.27 | 0.06 | -0.08 | -0.09 |
| Weighted Average Shares Outstanding | 405.44 Million | 405.26 Million | 405.26 Million | 405.26 Million | 405.26 Million | 205.7 Million |
| Weighted Average Shares Outstanding (Diluted) | 405.44 Million | 405.26 Million | 405.26 Million | 405.26 Million | 405.26 Million | 205.7 Million |
| Gross Margin | 0.94 | 0.93 | 0.94 | 0.95 | 0.91 | 0.85 |
| EBIT Margin | 0.11 | 0.17 | 0.29 | 0.21 | -0.03 | -0.01 |
| Profit Margin | 0.04 | 0.05 | 0.22 | 0.07 | -0.17 | -0.25 |
| EBITDA | 56.81 Million | 77.53 Million | 131.45 Million | 55.05 Million | -23.38 Million | -8.17 Million |
| Earnings Before Tax Margin | 0.01 | 0.13 | 0.21 | 0.15 | -0.13 | -0.28 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 159.74 Million | 154.28 Million | 70.79 Million | 143.81 Million | 496.11 Million | 119.09 Million |
| Cost of Revenue | 8.12 Million | 11.49 Million | 5.35 Million | 6.92 Million | 31.99 Million | 8.85 Million |
| Gross Profit | 151.62 Million | 142.78 Million | 65.44 Million | 136.89 Million | 464.12 Million | 110.24 Million |
| Operating Expenses | 116.71 Million | 144.71 Million | 100.36 Million | 160.51 Million | 492.71 Million | 130.95 Million |
| Selling, General and Administrative Expenses | 92.26 Million | 119.9 Million | 53.35 Million | 66.17 Million | - | 105.89 Million |
| Research and Development Expenses | 24.11 Million | 23.99 Million | 47.73 Million | 34.44 Million | - | 38.71 Million |
| Other Expenses | -336.92 Thousand | -822.02 Thousand | 1.01 Million | -160.51 Million | -492.71 Million | 800.15 Thousand |
| Cost and Expenses | 124.83 Million | 156.21 Million | 105.72 Million | 160.51 Million | 492.71 Million | 139.8 Million |
| Operating Income | 34.9 Million | -1.93 Million | -28.31 Million | -16.69 Million | 3.4 Million | -2.17 Million |
| Interest Expense | 4 Million | 3.69 Million | 2.79 Million | 2.63 Million | 7.17 Million | 1.49 Million |
| Income Tax Expense | 1.53 Million | -1.47 Million | -6.52 Million | -5.31 Million | -1.49 Million | -979.7 Thousand |
| Earnings before Tax | 32.16 Million | -3.42 Million | -27.29 Million | -13.95 Million | 15.92 Million | -1.37 Million |
| Net Income | 31.97 Million | -1.95 Million | -25.99 Million | -8.64 Million | 17.55 Million | 1.73 Million |
| Earnings Per Share Basic | 0.08 | -0.00 | -0.06 | -0.02 | - | 0.00 |
| Earnings Per Share Diluted | 0.08 | -0.00 | -0.06 | -0.02 | - | 0.00 |
| Weighted Average Shares Outstanding | 405.18 Million | 405.4 Million | 405.56 Million | 405.55 Million | 405.44 Million | 405.4 Million |
| Weighted Average Shares Outstanding (Diluted) | 405.18 Million | 405.4 Million | 405.56 Million | 405.54 Million | 405.44 Million | 405.4 Million |
| Gross Margin | 0.95 | 0.93 | 0.92 | 0.95 | 0.94 | 0.93 |
| EBIT Margin | 0.23 | 0.04 | -0.47 | 0.05 | - | -0.16 |
| Profit Margin | 0.20 | -0.01 | -0.37 | -0.06 | 0.04 | 0.01 |
| EBITDA | 36.17 Million | 6.88 Million | -33.37 Million | 6.66 Million | - | -19.38 Million |
| Earnings Before Tax Margin | 0.22 | -0.01 | -0.40 | -0.12 | 0.01 | -0.02 |
AQUEF
MHC-U
601518
AEXFF
JETMF
UCBJY